The company will not receive any proceeds from the sale of shares of common stock by the selling stockholders.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEXX:
- Lexaria’s DehydraTECH-Semaglutide Cuts GLP-1 Side Effects in Phase 1b Trial and Extends Cash Runway Into 2026
- Lexaria Bioscience achieves primary endpoint in Phase 1b study GLP-1-H24-4
- Lexaria Bioscience Secures $3.5 Million in Direct Offering to Boost R&D
- Lexaria Bioscience prices 2.66M share at the market offering at $1.315
- Lexaria Extends Agreement to Advance Drug Delivery Technology Evaluation